Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04818229 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects
A Phase 1 study of Autoimmune Diseases, sponsored by Connect Biopharma Australia Pty.
- Completed
- Registry status
- Phase 1
- Development phase
- 112
- Enrollment target
- 2
- Study locations
NCT04818229 is a Phase 1 study of Autoimmune Diseases that has completed, run by Connect Biopharma Australia Pty. The registered enrollment target is 112 participants, below the 974-participant average among 25 other Autoimmune Diseases trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT04818229, a Phase 1 study of Autoimmune Diseases, has completed, sponsored by Connect Biopharma Australia Pty.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 112 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will investigate the effects of therapeutic and supratherapeutic oral doses of CBP-307 on the QTc interval in healthy subjects.
Conditions Studied
Interventions
- DRUG CBP-307
- DRUG Placebo-matched CBP-307
- DRUG Moxifloxacin (Avelox)
- DRUG Placebo-matched Moxifloxacin
Study Locations (2)
Florida
- Clinical Pharmacology of Miami (CPMI), LLC - Hialeah
South Australia
- CMAX - Adelaide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2021-06-01 |
| Est. Completion | 2022-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04818229
The ClinicalTrials.gov registry entry for NCT04818229 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 974-participant average among 25 other Autoimmune Diseases trials with a reported enrollment target (89% lower). The listed sponsor is Connect Biopharma Australia Pty, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Autoimmune Diseases appearing as the primary indexed condition, and to 4 interventions - of which CBP-307 is the first listed.
NCT04818229 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, South Australia.
Frequently Asked Questions
What is clinical trial NCT04818229 about?
NCT04818229 is a clinical study titled "A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects". This study will investigate the effects of therapeutic and supratherapeutic oral doses of CBP-307 on the QTc interval in healthy subjects.
What is the current status of trial NCT04818229?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 112 participants. The study started on 2021-06-01. Estimated completion is 2022-03-30.
What conditions does trial NCT04818229 study?
This clinical trial studies the following conditions: Autoimmune Diseases.
What interventions are being tested in trial NCT04818229?
The interventions under investigation include: CBP-307 (DRUG), Placebo-matched CBP-307 (DRUG), Moxifloxacin (Avelox) (DRUG), Placebo-matched Moxifloxacin (DRUG).
Who is sponsoring clinical trial NCT04818229?
This trial is sponsored by Connect Biopharma Australia Pty, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04818229 being conducted?
This trial has 2 study locations across Florida, South Australia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autoimmune Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions
RECRUITING · Phase 1
-
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
RECRUITING · Phase 1
-
Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis
COMPLETED · Phase 1
-
Rheumatology Diet Study
RECRUITING
-
Collection and Distribution of Biospecimens for Novel Research Uses
RECRUITING
-
Ovarian Tissue Cryopreservation for Fertility Preservation
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.